Moreover, ATM has been implicated in enhanced epithelial-mesenchymal transition and metastatic potential in cisplatin-resistant non-small cell lung cancer (NSCLC) [44], and downregulation of Rad51 has been shown to reduce cisplatin resistance in breast cancer cells [45]. This evidence concerns the gene RAD51 and non-small cell lung carcinoma.